A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1896
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand ; volume:16 ; number:3 ; day:9 ; month:4 ; year:2018 ; pages:331-345 ; date:6.2018
Applied health economics and health policy ; 16, Heft 3 (9.4.2018), 331-345, 6.2018
- Urheber
-
Varghese, Lijoy
- Beteiligte Personen und Organisationen
-
Talbot, Louise
Govender, Andrea
Zhang, Xu-Hao
Mungall, Bruce A.
SpringerLink (Online service)
- DOI
-
10.1007/s40258-018-0387-5
- URN
-
urn:nbn:de:101:1-2018071322054367654402
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Varghese, Lijoy
- Talbot, Louise
- Govender, Andrea
- Zhang, Xu-Hao
- Mungall, Bruce A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
Severe polyserositis induced by the 13-valent pneumococcal conjugate vaccine: a case report
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial
Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
Reply to Farkouh RA et al. Comment on “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus Influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”
Correction to: Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
Severe polyserositis induced by the 13-valent pneumococcal conjugate vaccine: a case report
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial
Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
Reply to Farkouh RA et al. Comment on “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus Influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”
Correction to: Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
Severe polyserositis induced by the 13-valent pneumococcal conjugate vaccine: a case report
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial
Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
Reply to Farkouh RA et al. Comment on “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus Influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”